Akira Yabuno

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 4

Top Topics

Randomized Controlled Trial

Top Venues

Journal of gynecologic oncology

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Yuji Ikeda, Sho Sato, Akira Yabuno, Daisuke Shintani, Aiko Ogasawara, Maiko Miwa, Makda Getachew Zewde, Takashi Miyamoto, Keiichi Fujiwara, Yusuke Nakamura, Kosei Hasegawa
High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo. Journal of gynecologic oncology 31 (6) (2021)
Hirokazu Matsushita, Kosei Hasegawa, Katsutoshi Oda, Shogo Yamamoto, Kayo Asada, Takahiro Karasaki, Akira Yabuno, Akira Nishijima, Takahide Nejo, Yukari Kobayashi, Sho Sato, Yuji Ikeda, Manami Miyai, Yusuke Takahashi, Rui Yamaguchi, Keiichi Fujiwara, Hiroyuki Aburatani, Kazuhiro Kakimi
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. Journal for immunotherapy of cancer 8 (1) (2021)
Takashi Motohashi, Akira Yabuno, Hirofumi Michimae, Tetsuro Ohishi, Miwa Nonaka, Masashi Takano, Shin Nishio, Hiroyuki Fujiwara, Keiichi Fujiwara, Asumi Okumura, Toru Sugiyama, Tsutomu Tabata
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial. Journal of gynecologic oncology 32 (1) (2020)
Tadaaki Nishikawa, Kosei Hasegawa, Akira Yabuno, Hiroyuki Yoshida, Masanori Yasuda, Eito Kozawa, Keiichi Fujiwara
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. Journal of gynecologic oncology 28 (1) (2017)